• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Skin And Soft Tissue Infections - Pipeline Review, H2 2012 Product Image

Skin And Soft Tissue Infections - Pipeline Review, H2 2012

  • Published: December 2012
  • 46 pages
  • Global Markets Direct

Skin And Soft Tissue Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Skin And Soft Tissue Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Skin And Soft Tissue Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin And Soft Tissue Infections. Skin And Soft Tissue Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Skin And Soft Tissue Infections.
- A review of the Skin READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Skin And Soft Tissue Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Skin And Soft Tissue Infections 7
Skin And Soft Tissue Infections Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Skin And Soft Tissue Infections Therapeutics – Products under Development by Companies 13
Companies Involved in Skin And Soft Tissue Infections Therapeutics Development 14
Rib-X Pharmaceuticals, Inc. 14
Basilea Pharmaceutica Ltd. 15
MerLion Pharmaceuticals Pte Ltd 16
Nitric Biotherapeutics, Inc. 17
Atox Bio Inc. 18
Enanta Pharmaceuticals, Inc. 19
Skin And Soft Tissue Infections – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
RX-04 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
finafloxacin + Small Molecule Antimicrobial - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
EDP-322 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
AB-103 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
nitric oxide - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ceftobiprole medocaril - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Skin And Soft Tissue Infections Therapeutics – Drug Profile Updates 34
Skin And Soft Tissue Infections Therapeutics - Dormant Products 37
Skin And Soft Tissue Infections – Product Development Milestones 38
Featured News & Press Releases 38
Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial 38
Sep 10, 2012: Atox Bio’s AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections 38
Oct 25, 2011: Atox Bio Receives Orphan Drug Designation For AB103 For Treatment Of Necrotizing Soft Tissue Infections 39
May 05, 2011: Furiex To Present Two Abstracts Featuring JNJ-Q2 At Joint Meeting Of ECCMID And ICC 39
Nov 08, 2010: Abbott Presents Data Exploring Relationship of Physical Function to Inflammation and Structural Damage in RA 40
Oct 25, 2010: Intercell Announces Positive Results From Phase II Pseudomonas Aeruginosa Investigational Vaccine Study For Certain Hospital-Acquired Infections 41
Oct 15, 2010: Cempra To Present New Data On TAKSTA At Annual Meeting Of Infectious Diseases Society Of America 42
Dec 15, 2009: Rib-X Signs Collaborative Agreement On Delafloxacin With Massachusetts General Hospital 42
Mar 04, 2009: NovaBay To Present New Preclinical Data Of NVC-422 At AAD Annual Meeting 43
Nov 30, 1998: Ascent Pediatrics to Co-promote Omnicef (cefdinir) With Warner-Lambert. 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products Under Development for Skin And Soft Tissue Infections, H2 2012 7
Products under Development for Skin And Soft Tissue Infections – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Mid Clinical Stage Development, H2 2012 10
Comparative Analysis by Early Clinical Stage Development, H2 2012 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Rib-X Pharmaceuticals, Inc., H2 2012 14
Basilea Pharmaceutica Ltd., H2 2012 15
MerLion Pharmaceuticals Pte Ltd, H2 2012 16
Nitric Biotherapeutics, Inc., H2 2012 17
Atox Bio Inc., H2 2012 18
Enanta Pharmaceuticals, Inc., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Skin And Soft Tissue Infections Therapeutics – Drug Profile Updates 34
Skin And Soft Tissue Infections Therapeutics – Dormant Products 37

List of Figures
Number of Products under Development for Skin And Soft Tissue Infections, H2 2012 7
Products under Development for Skin And Soft Tissue Infections – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Mid Clinical Stage Products, H2 2012 10
Early Clinical Stage Products, H2 2012 11
Discovery and Pre-Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos